¿Emergencia médica?¿Emergencia? Llame al 911. Salas de emergencias más cercanasEmergencias cercanas

Empresa farmacéutica (etiquetadora ante la FDA)

Zydus Pharmaceuticals USA Inc.

Código de etiquetadora NDCs: 68382, 70710

¿Qué es una etiquetadora?

La empresa cuyo nombre aparece en el envase y en el directorio de códigos nacionales de medicamentos (NDC) de la FDA. Puede fabricar el medicamento o vender uno fabricado por otra empresa. La primera parte de cada código NDC identifica a la etiquetadora.

Solo datos oficiales de la FDA

Los productos, aprobaciones y retiros vienen de la FDA (directorio NDC, Drugs@FDA, informes de retiros). Los retiros se vinculan a esta empresa por el código NDC del producto retirado.

Si tiene preguntas sobre su medicamento, hable con su médico o farmacéutico. En una emergencia, llame al 911.

De un vistazo

621Productos (NDC)

Medicamentos con receta

Mostrar los otros 158 medicamentos

Solicitudes de la FDA de estos productos

  • NDA: Solicitud de nuevo medicamento (NDA): así se aprueba un medicamento nuevo, normalmente de marca.
  • ANDA: Solicitud abreviada (ANDA): así se aprueba una versión genérica.
  • BLA: Solicitud de licencia de productos biológicos (BLA): así se aprueba un medicamento biológico (hecho a partir de células vivas).
AprobadaSolicitudMedicamentoPatrocinador
19 de octubre de 2026ANDA220407 Estradiol and levonorgestrel
ESTRADIOL AND LEVONORGESTREL
Zydus Pharms
20 de agosto de 2026ANDA220873 Ascorbic acid
ASCORBIC ACID
Zydus Pharms
21 de julio de 2026ANDA220447 Fluvoxamine maleate
FLUVOXAMINE MALEATE
Zydus Pharms
11 de junio de 2026ANDA219287 Gadobutrol
GADOBUTROL
Viwit Pharm
1 de junio de 2026ANDA218651 Fluorescein (fluorescein sodium)
FLUORESCEIN SODIUM
Zydus Lifesciences
7 de mayo de 2026ANDA217191 Hydrocortisone
HYDROCORTISONE SODIUM SUCCINATE
Zydus Pharms
23 de abril de 2026ANDA220568 Glycerol phenylbutyrate
GLYCEROL PHENYLBUTYRATE
Navinta LLC
6 de abril de 2026ANDA211582 Dapagliflozin
DAPAGLIFLOZIN
Zydus Pharms
4 de marzo de 2026ANDA215864 Calcitonin salmon
CALCITONIN-SALMON
Zydus Pharms
17 de febrero de 2026ANDA213981 Bosentan
BOSENTAN
Zydus Pharms
17 de febrero de 2026ANDA220418 Sodium phenylbutyrate
SODIUM PHENYLBUTYRATE
Navinta LLC
29 de enero de 2026ANDA220275 Sertraline hydrochloride
SERTRALINE HYDROCHLORIDE
Zydus Lifesciences
14 de enero de 2026ANDA216281 Eltrombopag
ELTROMBOPAG OLAMINE
Zydus Pharms
18 de diciembre de 2025BLA761473 Ranibizumab-eqrn
NUFYMCO
Formycon AG
24 de noviembre de 2025ANDA219252 Verapamil hydrochloride
VERAPAMIL HYDROCHLORIDE
Zydus Lifesciences
14 de noviembre de 2025ANDA217468 Diazepam
DIAZEPAM
Navinta LLC
27 de octubre de 2025ANDA219931 Sevelamer carbonate
SEVELAMER CARBONATE
Navinta LLC
3 de octubre de 2025ANDA220042 Deflazacort
DEFLAZACORT
Zydus Lifesciences
22 de mayo de 2025ANDA216633 Isotretinoin
ISOTRETINOIN
Zydus Pharms
13 de mayo de 2025ANDA217880 Maraviroc
MARAVIROC
Navinta LLC
7 de mayo de 2025ANDA208468 Glatiramer acetate
GLATIRAMER ACETATE
Chemi Spa
8 de abril de 2025ANDA219254 Deflazacort
JAYTHARI
Zydus Lifesciences
14 de marzo de 2025ANDA219111 Miglustat
MIGLUSTAT
Navinta LLC
3 de marzo de 2025ANDA218719 Dasatinib
DASATINIB
Zydus Pharms
3 de febrero de 2025ANDA218966 Sevelamer hydrochloride
SEVELAMER HYDROCHLORIDE
Navinta LLC
Mostrar las otras 100 solicitudes
AprobadaSolicitudMedicamentoPatrocinador
23 de octubre de 2024NDA218711 Docetaxel
BEIZRAY
Zhuhai
29 de agosto de 2024ANDA217893 Scopolamine
SCOPOLAMINE
Zydus Pharms
18 de julio de 2024NDA216778 Sitagliptin and metformin hydrochloride
ZITUVIMET XR
Zydus Lifesciences
9 de julio de 2024ANDA213719 Sacubitril and valsartan
SACUBITRIL AND VALSARTAN
Zydus Pharms
13 de marzo de 2024ANDA217275 Chlorpromazine hydrochloride
CHLORPROMAZINE HYDROCHLORIDE
Zydus Pharms
24 de enero de 2024ANDA203934 Gabapentin
GABAPENTIN
Zydus Pharms
5 de diciembre de 2023ANDA215636 Methylene blue
METHYLENE BLUE
Zydus Lifesciences
29 de noviembre de 2023ANDA213442 Ivabradine
IVABRADINE HYDROCHLORIDE
Zydus Pharms
3 de noviembre de 2023NDA216743 Sitagliptin and metformin hydrochloride
ZITUVIMET
Zydus Lifesciences
18 de octubre de 2023NDA211566 Sitagliptin
ZITUVIO
Zydus Lifesciences
4 de octubre de 2023ANDA214290 Sugammadex
SUGAMMADEX SODIUM
Zydus Pharms
14 de septiembre de 2023ANDA214594 Norelgestromin and ethinyl estradiol
ETHINYL ESTRADIOL AND NORELGESTROMIN
Zydus Pharms
29 de agosto de 2023ANDA211568 Isotretinoin
ISOTRETINOIN
Zydus Pharms
22 de agosto de 2023ANDA217074 Zinc sulfate
ZINC SULFATE
Zydus Pharms
2 de agosto de 2023ANDA216184 Indomethacin
INDOMETHACIN
Zydus Lifesciences
26 de julio de 2023ANDA208980 Plerixafor
PLERIXAFOR
Zydus Pharms
14 de julio de 2023ANDA217526 Sodium phenylacetate and sodium benzoate
SODIUM PHENYLACETATE AND SODIUM BENZOATE
Navinta LLC
3 de julio de 2023ANDA211747 Oxcarbazepine
OXCARBAZEPINE
Zydus
12 de junio de 2023ANDA216723 Varenicline tartrate
VARENICLINE TARTRATE
Zydus
8 de junio de 2023ANDA217592 Balsalazide disodium
BALSALAZIDE DISODIUM
Zydus Lifesciences
7 de junio de 2023ANDA206055 Esomeprazole
ESOMEPRAZOLE MAGNESIUM
Zydus Pharms
20 de abril de 2023ANDA217656 Icosapent ethyl
ICOSAPENT ETHYL
Zydus Lifesciences
17 de abril de 2023ANDA204379 Estradiol
ESTRADIOL
Zydus Pharms
4 de abril de 2023ANDA211069 Acetazolamide
ACETAZOLAMIDE
Zydus Lifesciences
29 de marzo de 2023ANDA202985 Estradiol
ESTRADIOL
Zydus Pharms
24 de marzo de 2023ANDA217066 Levothyroxine
LEVOTHYROXINE SODIUM
Zydus Pharms
23 de marzo de 2023ANDA214131 Lubiprostone
LUBIPROSTONE
Zydus Pharms
14 de marzo de 2023ANDA209829 Tofacitinib
TOFACITINIB CITRATE
Zydus Pharms
7 de marzo de 2023ANDA212693 Erythromycin
ERYTHROMYCIN
Zydus Lifesciences
2 de marzo de 2023ANDA214671 Vigabatrin
VIGABATRIN
Zydus Lifesciences
22 de febrero de 2023ANDA206047 Pitavastatin
PITAVASTATIN CALCIUM
Zydus Pharms
28 de diciembre de 2022ANDA213003 Triazolam
TRIAZOLAM
Zydus Pharms
21 de diciembre de 2022ANDA214302 Selexipag
SELEXIPAG
Zydus Lifesciences
1 de diciembre de 2022ANDA206241 Estradiol
ESTRADIOL
Zydus Pharms
28 de noviembre de 2022ANDA208949 Topiramate
TOPIRAMATE
Zydus
24 de octubre de 2022ANDA215241 Micafungin
MICAFUNGIN SODIUM
Zydus Pharms
21 de octubre de 2022ANDA217038 Ketorolac tromethamine
KETOROLAC TROMETHAMINE
Zydus Lifesciences
3 de octubre de 2022ANDA214501 Brivaracetam
BRIVARACETAM
Zydus Pharms
29 de septiembre de 2022ANDA209488 Mirabegron
MIRABEGRON
Zydus Pharms
29 de septiembre de 2022ANDA215708 Sildenafil
SILDENAFIL CITRATE
Zydus Lifesciences
12 de septiembre de 2022ANDA210154 Lenalidomide
LENALIDOMIDE
Zydus Pharms
1 de septiembre de 2022ANDA211135 Riociguat
RIOCIGUAT
Msn
30 de agosto de 2022ANDA215622 Venlafaxine
VENLAFAXINE HYDROCHLORIDE
Zydus Pharms
8 de agosto de 2022ANDA216495 Prochlorperazine
PROCHLORPERAZINE MALEATE
Zydus Lifesciences
29 de junio de 2022ANDA209465 Lacosamide
LACOSAMIDE
Zydus Pharms
3 de junio de 2022ANDA216441 Famotidine
FAMOTIDINE
Zydus Pharms
11 de mayo de 2022ANDA215750 Diclofenac
DICLOFENAC POTASSIUM
Umedica
2 de mayo de 2022ANDA210204 Bortezomib
BORTEZOMIB
Zydus Pharms
15 de abril de 2022ANDA214655 Cyanocobalamin
CYANOCOBALAMIN
Zydus Pharms
10 de marzo de 2022ANDA215223 Colestipol hydrochloride
COLESTIPOL HYDROCHLORIDE
Zydus Pharms
10 de febrero de 2022ANDA208303 Roflumilast
ROFLUMILAST
Zydus Pharms
19 de enero de 2022ANDA215707 Vigabatrin
VIGABATRIN
Zydus Lifesciences
17 de noviembre de 2021ANDA215037 Nelarabine
NELARABINE
Zydus Pharms
19 de agosto de 2021ANDA214264 Tofacitinib
TOFACITINIB CITRATE
Zydus Pharms
12 de agosto de 2021ANDA208954 Mesalamine
MESALAMINE
Zydus Pharms
29 de julio de 2021ANDA215234 Fulvestrant
FULVESTRANT
Zydus Pharms
27 de mayo de 2021ANDA214552 Fluphenazine hydrochloride
FLUPHENAZINE HYDROCHLORIDE
Zydus Lifesciences
21 de abril de 2021ANDA214184 Propafenone hydrochloride
PROPAFENONE HYDROCHLORIDE
Zydus Lifesciences
6 de abril de 2021ANDA211224 Macitentan
MACITENTAN
Zydus Lifesciences
24 de febrero de 2021ANDA213441 Nortriptyline hydrochloride
NORTRIPTYLINE HYDROCHLORIDE
Zydus Lifesciences
18 de febrero de 2021ANDA211818 Droxidopa
DROXIDOPA
Zydus Pharms
22 de enero de 2021ANDA214803 Liothyronine sodium
LIOTHYRONINE SODIUM
Zydus Lifesciences
22 de octubre de 2020ANDA208884 Albuterol sulfate
ALBUTEROL SULFATE
Zydus Pharms
16 de octubre de 2020ANDA214295 Ursodiol
URSODIOL
Zydus Lifesciences
15 de octubre de 2020ANDA214215 Verapamil hydrochloride
VERAPAMIL HYDROCHLORIDE
Zydus Pharms
14 de octubre de 2020ANDA207994 Fingolimod
FINGOLIMOD HYDROCHLORIDE
Zydus Pharms
24 de septiembre de 2020ANDA210538 Dimethyl fumarate
DIMETHYL FUMARATE
Zydus Pharms
17 de septiembre de 2020ANDA210395 Potassium chloride
POTASSIUM CHLORIDE
Zydus Pharms
10 de septiembre de 2020ANDA212299 Doxorubicin hydrochloride
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Zydus Lifesciences
1 de septiembre de 2020ANDA213055 Midodrine hydrochloride
MIDODRINE HYDROCHLORIDE
Zydus Lifesciences
11 de agosto de 2020ANDA207759 Sevelamer carbonate
SEVELAMER CARBONATE
Zydus Pharms
23 de junio de 2020ANDA213957 Meclizine hydrochloride
MECLIZINE HYDROCHLORIDE
Zydus Lifesciences
16 de abril de 2020ANDA213065 Erlotinib
ERLOTINIB HYDROCHLORIDE
Zydus Pharms
6 de abril de 2020ANDA205232 Perphenazine
PERPHENAZINE
Zydus Pharms
1 de abril de 2020ANDA207763 Lamotrigine
LAMOTRIGINE
Zydus Pharms
28 de febrero de 2020ANDA212689 Emtricitabine and tenofovir disoproxil fumarate
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Zydus Pharms
12 de febrero de 2020ANDA208953 Mesalamine
MESALAMINE
Zydus Pharms
17 de enero de 2020ANDA213368 Chlorpromazine hydrochloride
CHLORPROMAZINE HYDROCHLORIDE
Zydus Lifesciences
20 de noviembre de 2019ANDA211383 Deferasirox
DEFERASIROX
Zydus Pharms
20 de noviembre de 2019ANDA213057 Isosorbide dinitrate
ISOSORBIDE DINITRATE
Zydus Lifesciences
4 de noviembre de 2019ANDA212171 Cisatracurium besylate
CISATRACURIUM BESYLATE
Zydus Pharms
22 de octubre de 2019ANDA211180 Haloperidol decanoate
HALOPERIDOL DECANOATE
Zydus Pharms
7 de octubre de 2019ANDA207765 Colesevelam hydrochloride
COLESEVELAM HYDROCHLORIDE
Zydus Pharms
22 de julio de 2019ANDA211567 Ramelteon
RAMELTEON
Zydus Pharms
22 de mayo de 2019ANDA206296 Esomeprazole
ESOMEPRAZOLE MAGNESIUM
Zydus Pharms
10 de mayo de 2019ANDA207813 Chlorthalidone
CHLORTHALIDONE
Zydus Pharms
26 de abril de 2019ANDA207760 Bosentan
BOSENTAN
Zydus Pharms
24 de abril de 2019ANDA212308 Leflunomide
LEFLUNOMIDE
Zydus Lifesciences
28 de marzo de 2019ANDA210058 Ambrisentan
AMBRISENTAN
Zydus Pharms
26 de marzo de 2019ANDA206693 Tadalafil
TADALAFIL
Zydus Pharms
19 de marzo de 2019ANDA208052 Lurasidone hydrochloride
LURASIDONE HYDROCHLORIDE
Zydus Pharms
11 de marzo de 2019ANDA208445 Potassium chloride
POTASSIUM CHLORIDE
Zydus Pharms
8 de marzo de 2019ANDA210028 Atenolol and chlorthalidone
ATENOLOL AND CHLORTHALIDONE
Zydus Pharms
4 de marzo de 2019ANDA206318 Rivastigmine
RIVASTIGMINE
Zydus Pharms
20 de febrero de 2019ANDA210189 Phytonadione
PHYTONADIONE
Zydus Lifesciences
19 de febrero de 2019ANDA211519 Colchicine (colchiceine)
COLCHICINE
Zydus Pharms
11 de febrero de 2019ANDA208358 Triamterene and hydrochlorothiazide
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Cadila
7 de febrero de 2019ANDA205571 Carbamazepine
CARBAMAZEPINE
Zydus Pharms
16 de enero de 2019ANDA205301 Acetazolamide
ACETAZOLAMIDE
Cadila
11 de enero de 2019ANDA208885 Betamethasone dipropionate
BETAMETHASONE DIPROPIONATE
Zydus Pharms

Se muestran las 125 más recientes de 237 solicitudes. Listas completas: Drugs@FDA →

El patrocinador es la empresa titular de la solicitud ante la FDA; puede ser distinta de la etiquetadora.

Cronología de retiros

2026

  1. 1 de octubre de 2026 · Clase II · En curso · D-0039-2027 · Hydrocortisone

    Failed Impurities/Degradation Specifications.

    Hydrocortisone Sodium Succinate for Injection, USP 100 mg/vial, 1 Vial, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Vadodara - 391510 India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534,

  2. 5 de agosto de 2026 · Clase II · En curso · D-0745-2026 · Mirabegron

    CGMP: Due to Out of Specification (OOS) result for N-Nitroso Mirabegron impurity.

    Mirabegron Extended-Release Tablets, 25 mg, 30-count bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Matoda, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-

  3. 29 de abril de 2026 · Clase II · En curso · D-0544-2026 · Erythromycin

    CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

    Erythromycin Tablets, USP, 250 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; a) 30 count bottles (

  4. 29 de abril de 2026 · Clase II · En curso · D-0545-2026 · Erythromycin

    CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

    Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; (NDC 70710-1048-3).

  5. 9 de marzo de 2026 · Clase II · En curso · D-0400-2026 · Icosapent ethyl

    Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

    Icosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-1592-7

2025

  1. 19 de diciembre de 2025 · Clase III · En curso · D-0247-2026 · Trazodone hydrochloride

    Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.

    traZODONE Hydrochloride Tablets, USP, 100mg, 1,000 Tablets, Rx only, Manufactured by: Zydus Lifesciences Ltd., India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-806-10

  2. 23 de octubre de 2025 · Clase II · En curso · D-0159-2026 · Bromocriptine mesylate

    Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.

    Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06

  3. 24 de septiembre de 2025 · Clase II · En curso · D-0001-2026 · Entecavir

    Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity

    Entecavir Tablets, USP, 0.5 mg, 30-count bottle, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-920-06.

  4. 24 de septiembre de 2025 · Clase II · En curso · D-0002-2026 · Entecavir

    Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity

    Entecavir Tablets, USP, 1 mg, 30-count bottle, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-921-06.

  5. 4 de septiembre de 2025 · Clase II · En curso · D-0657-2025 · Entecavir

    Failed Impurity/Degradation Specifications

    Entecavir Tablets, USP, 1 mg, 30 Tablets, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-921-06.

Mostrar los 50 retiros anteriores

2025

  1. 4 de septiembre de 2025 · Clase II · En curso · D-0656-2025 · Entecavir

    Failed Impurity/Degradation Specifications

    Entecavir Tablets, USP, 0.5 mg, 30 Tablets, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-920-06.

  2. 3 de septiembre de 2025 · Clase II · En curso · D-0636-2025 · Chlorpromazine hydrochloride

    CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

    Chlorpromazine Hydrochloride Tablets, USP, 100 mg, 100-count bottle, Rx only, Manufactured By: Zydus Lifesciences Ltd., Baddi, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-113

  3. 3 de septiembre de 2025 · Clase II · En curso · D-0630-2025 · Chlorpromazine hydrochloride

    CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

    Chlorpromazine Hydrochloride Tablets, USP, 10 mg, 100-count bottle, Rx only, Manufactured By: Zydus Lifesciences Ltd., Baddi, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-1129

  4. 3 de septiembre de 2025 · Clase II · En curso · D-0634-2025 · Chlorpromazine hydrochloride

    CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

    Chlorpromazine Hydrochloride Tablets, USP, 50 mg, 100-count bottle, Rx only, Manufactured By: Zydus Lifesciences Ltd., Baddi, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-1131

  5. 3 de septiembre de 2025 · Clase II · En curso · D-0632-2025 · Chlorpromazine hydrochloride

    CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

    Chlorpromazine Hydrochloride Tablets, USP, 25 mg, 100-count bottle, Rx only, Manufactured By: Zydus Lifesciences Ltd., Baddi, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-1130

  6. 3 de septiembre de 2025 · Clase II · En curso · D-0638-2025 · Chlorpromazine hydrochloride

    CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

    Chlorpromazine Hydrochloride Tablets, USP, 200 mg, 100-count bottle, Rx only, Manufactured By: Zydus Lifesciences Ltd., Baddi, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. NDC: 70710-113

  7. 27 de agosto de 2025 · Clase II · En curso · D-0623-2025 · Succinylcholine

    Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.

    Succinylcholine Chloride Injection, USP 200 mg/10 mL (20 mg/mL), Rx only, 10 mL Multiple-dose Vial, Sterile, Manufactured by Zydus Lifesciences Ltd, Vadodara, India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Penn

  8. 30 de mayo de 2025 · Clase II · Completado · D-0497-2025 · Icosapent ethyl

    Failed Tablet/Capsule specifications; a product complaint was reported for burnt or melted capsules. This was determined to be a result of oxidation by leakage of capsule contents.

    Icosapent Ethyl Capsules 1 gram, 120 Capsules per Bottle, Rx Only, Manufactured by Doppel Farmaceutici s.r.l., Piacenza, Italy, Distributed by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1592-7.

  9. 13 de mayo de 2025 · Clase II · En curso · D-0442-2025 · Esomeprazole

    Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing during long term stability.

    Esomeprazole Magnesium for Delayed-Release Oral Suspension, 40 mg, 30-count Single-Dose Packets per carton, Rx Only, Manufactured by: Zydus Lifesciences Ltd. Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA)

  10. 13 de mayo de 2025 · Clase II · En curso · D-0443-2025 · Esomeprazole

    Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing during long term stability.

    Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg, 30-count single dose packets per carton, Rx Only, Manufactured by: Zydus Lifesciences Ltd. Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA)

  11. 3 de abril de 2025 · Clase II · En curso · D-0361-2025 · Chlorpromazine hydrochloride

    CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit

    chlorproMAZINE Hydrochloride Tablets, USP 10 mg, Rx Only, 100 Tablets bottles, Manufactured by: Zydus Lifesciences Ltd., Baddi, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-112

  12. 21 de marzo de 2025 · Clase II · Completado · D-0310-2025 · Venlafaxine

    Presence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.

    Venlafaxine Tablets, USP, 75 mg, 100 Tablets, Rx only, Mfg. by: Zydus Lifesciences Ltd, Ahmedabad, India, Dist. by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-021-01.

  13. 13 de febrero de 2025 · Clase II · En curso · D-0256-2025 · Nelarabine

    Failed Impurities/Degradation Specifications

    Nelarabine Injection, 250mg/50mL, (5mg/mL), packaged in: a) 50 mL Single-Dose Vial, NDC 70710-1839-1; b) 6 x 50 mL Single-Dose Vial, NDC 70710-1839-8, Rx only, Manufactured by Zydus Lifesciences Ltd, Ahmedabad, India, Di

  14. 13 de febrero de 2025 · Clase II · En curso · D-0255-2025 · Nelarabine

    Failed Impurities/Degradation Specifications

    Nelarabine Injection, 250mg/50mL, (5mg/mL), packaged in: a) 50 mL Single-Dose Vial, NDC 70710-1726-1; b) 6 x 50 mL Single-Dose Vial, NDC 70710-1726-8, Rx only, Manufactured by Zydus Lifesciences Ltd, Ahmedabad, India, Di

2024

  1. 14 de noviembre de 2024 · Clase III · En curso · D-0102-2025 · Esomeprazole

    Labeling: Not Elsewhere Classified - Wrong NDC number

    Esomeprazole Magnesium for Delayed-Release Oral Suspension 40 mg, 30 Single-Dose Packets, Rx Only, Manufactured by: Zydus Lifesciences Ltd. Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington,

  2. 2 de julio de 2024 · Clase III · En curso · D-0593-2024 · Verapamil hydrochloride

    Cross contamination with other products.

    Verapamil Hydrochloride Injection, USP 10 mg/4 mL (2.5 mg/mL), 5 x 4 mL Single-Dose Vial per carton, Rx Only, Manufactured by: Zydus Lifesciences Ltd. Vadodara, India, Distributed by: Zydus Pharmaceuticals (USA)Inc., Pen

  3. 2 de julio de 2024 · Clase III · En curso · D-0592-2024 · Verapamil hydrochloride

    Cross contamination with other products.

    Verapamil Hydrochloride Injection, USP 5 mg / 2mL(2.5 mg/mL), packaged as (a) 25x2 mL Single-Dose Vial per carton, Vial NDC: 70710-1643-1; Carton NDC 70710-1643-7; (b) 5x2 mL Single-Dose Vial per carton, Vial NDC: 70710-

  4. 21 de junio de 2024 · Clase II · Cerrado por la FDA · D-0617-2024 · Venlafaxine

    Failed Dissolution Specifications: Out-of-specification results observed for dissolution testing at the 8-hour and 12-hour pull intervals.

    Venlafaxine Hydrochloride Extended-Release Capsules, USP 37.5mg, packaged in a) 90-count bottles (NDC 68382-034-16) and b)1000-count bottles (NDC 68382-034-10), Rx only, Mfg. by: Zydus Lifesciences Ltd. Ahmedabad, India;

  5. 16 de mayo de 2024 · Clase III · En curso · D-0543-2024 · Estradiol

    Failed Impurities/Degradation Specifications.

    Estradiol Transdermal System, USP (Twice-Weekly) 0.025mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1191-

  6. 16 de mayo de 2024 · Clase III · En curso · D-0542-2024 · Estradiol

    Failed Impurities/Degradation Specifications.

    Estradiol Transdermal System, USP (Twice-Weekly) 0.0375mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1192

2023

  1. 19 de octubre de 2023 · Clase II · Completado · D-0097-2024 · Oxybutynin

    Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

    Oxybutynin Chloride Extended-Release Tablet USP, 10 mg, 100 count bottles Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-256-01.

  2. 19 de octubre de 2023 · Clase II · Completado · D-0098-2024 · Oxybutynin

    Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

    Oxybutynin Chloride Extended-Release Tablet USP, 15 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-257-01.

  3. 19 de octubre de 2023 · Clase II · Completado · D-0096-2024 · Oxybutynin

    Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.

    Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-255-01

  4. 21 de septiembre de 2023 · Clase II · Cerrado por la FDA · D-0038-2024 · Oxybutynin

    Failed Dissolution Specifications

    Oxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tablets (NDC 68382-256-05) bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India, Distributed by:

2022

  1. 15 de julio de 2022 · Clase II · Cerrado por la FDA · D-1351-2022 · Fulvestrant

    Failed Impurities/Degradation Specifications

    Fulvestrant Injection 250mg/5mL (50 mg/mL), Contains 2 Single-Dose Prefilled Syringes, Rx Only, Product of India, Manufactured by: Cadila Healthcare Limited, Ahmadabad, India, Distributed by: Zydus Pharmaceuticals (USA )

2021

  1. 13 de agosto de 2021 · Clase II · Cerrado por la FDA · D-0753-2021 · Carvedilol

    Presence of Foreign Tablets/Capsules; report of two Paroxetine tablets were found in the bottle

    Carvedilol Tablets, USP 25 mg, 500 Tablets bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd., India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 0853, NDC 68382-095-05

  2. 18 de febrero de 2021 · Clase I · Cerrado por la FDA · D-0315-2021 · Acyclovir

    Crystallization: customer complaints for crystallization in finished product.

    Acyclovir Sodium Injection 1000mg/20mL (50mg/mL) vial NDC 68382-049-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 20mL Single-Dose Vials per pack NDC 68382-049-10, Rx only, Manufactured

  3. 18 de febrero de 2021 · Clase I · Cerrado por la FDA · D-0316-2021 · Acyclovir

    Crystallization: customer complaints for crystallization in finished product.

    Acyclovir Sodium Injection 500mg/10mL (50mg/mL) vial NDC 68382-048-01, For Intravenous Infusion Only MUST BE DILUTED PRIOR TO USE, packaged in 10 x 10mL Single-Dose Vials per pack NDC 68382-048-10, Rx only, Manufactured

2020

  1. 3 de diciembre de 2020 · Clase II · Cerrado por la FDA · D-0146-2021 · Lansoprazole

    Failed Dissolution Specifications

    Lansoprazole Delayed-Release Orally Disintegrating Tablets, 30 mg, 100 Tablets (10 x 10 unit-dose) blister pack, Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA

  2. 3 de diciembre de 2020 · Clase II · Cerrado por la FDA · D-0145-2021 · Lansoprazole

    Failed Dissolution Specifications

    Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg, 100 Tablets (10x10 unit dose) blister pack, Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA In

  3. 27 de octubre de 2020 · Clase II · Cerrado por la FDA · D-0074-2021 · Lansoprazole

    Failed Dissolution Specification

    Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg, 100-count carton (10 x10 unit-dose), Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India, Distributed by: Zydus Pharmaceuticals USA Inc. Pen

  4. 27 de octubre de 2020 · Clase II · Cerrado por la FDA · D-0075-2021 · Lansoprazole

    Failed Dissolution Specification

    Lansoprazole Delayed-Release Orally Disintegrating Tablets 30 mg, 100-count carton (10 x10 unit-dose), Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India, Distributed by: Zydus Pharmaceuticals USA Inc. Pen

2019

  1. 6 de mayo de 2019 · Clase II · Cerrado por la FDA · D-1441-2019 · Anastrozole

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    Anastrozole Tablets, USP, 1 mg, 1,000-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534. NDC 68382-209-10

  2. 6 de mayo de 2019 · Clase II · Cerrado por la FDA · D-1440-2019 · Anastrozole

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    ANASTROZOLE Tablets, 1 mg, Rx Only, 30-count bottle, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534 NDC 68382-209-06

  3. 6 de mayo de 2019 · Clase II · Cerrado por la FDA · D-1453-2019 · Methylprednisolone

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    MethylPREDNISolone Tablets, USP 8 mg, 25 tablets, Rx Only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India NDC 68382-917-11

  4. 6 de mayo de 2019 · Clase II · Cerrado por la FDA · D-1451-2019 · Methylprednisolone

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    MethylPREDNISolone Tablets, USP 32 mg, 25 tablets, Rx Only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India NDC 68382-919-11

  5. 6 de mayo de 2019 · Clase II · Cerrado por la FDA · D-1448-2019 · Methylprednisolone

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    MethylPREDNISolone Tablets, USP, 4 mg, 100 tablets, Rx only, Manufactured by: Cadila Healthcare Ltd Ahmedabad, India NDC 68382-916-01

  6. 6 de mayo de 2019 · Clase II · Cerrado por la FDA · D-1450-2019 · Methylprednisolone

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    MethylPREDNISolone Tablets, USP 16 mg, 50 tablets, Rx only, Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India NDC 68382-918-18

  7. 6 de mayo de 2019 · Clase II · Cerrado por la FDA · D-1449-2019 · Methylprednisolone

    CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

    MethylPREDNISolone Tablets, USP 4 mg per tablet, 21 Tablets dosepack, Rx Only, Made in India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08534. NDC 68382-916-34

  8. 25 de abril de 2019 · Clase II · Cerrado por la FDA · D-1273-2019 · Carvedilol

    Labeling; Label Mix-up; report received of one bottle labeled as Acyclovir Tablets USP 400 mg actually contained Carvedilol Tablets 6.25 mg

    Carvedilol Tablets, USP, 6.25 mg, 500 count bottles, Rx Only Manufactured by: Cadila Healthcare Ltd., India Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ USA 08534 NDC 68382-093-05

  9. 25 de abril de 2019 · Clase II · Cerrado por la FDA · D-1272-2019 · Acyclovir

    Labeling; Label Mix-up; report received of one bottle labeled as Acyclovir Tablets USP 400 mg actually contained Carvedilol Tablets 6.25 mg

    Acyclovir Tablets, USP, 400 mg, 100 count bottles, Rx Only Manufactured by: Cadila Healthcare Ltd., India Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ USA 08534 NDC 68382-791-01

  10. 22 de abril de 2019 · Clase III · Cerrado por la FDA · D-1242-2019 · Carvedilol

    Presence of Foreign Tablets/Capsules: Customer complaint for a small, solid, light yellow substance, identified as a fragmented tablet of another drug product, found mixed with tablets in a bottle of Carvedilol tablets 3.125mg.

    Carvedilol Tablets, USP, 3.125 mg, 500-count bottle, Rx Only, Manufactured by: Cadila Healthcare Ltd., India; Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; NDC 68382-092-05

2017

  1. 20 de noviembre de 2017 · Clase II · Cerrado por la FDA · D-0101-2018 · Paroxetine

    Presence of Foreign Tablets/Capsules: Risperidone Tablets were found in bottle of Paroxetine Tablets

    Paroxetine Tablets USP, 30 mg, a) 30 count (NDC 68382-099-06), b) 500 count (NDC 68382-099-05), and c) 1000 count (NDC 68382-099-10) count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Ahmedabad, India Distri

  2. 18 de agosto de 2017 · Clase II · Cerrado por la FDA · D-1137-2017 · Paroxetine

    Presence of Foreign tablets/capsules: risperidone Tablets were found in bottle of paroxetine Tablets

    Paroxetine tablets USP, 30mg, 30-count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA, Inc., Pennington, NJ 08534, NDC 68382-099-06, UPC 3 6838209906

  3. 6 de marzo de 2017 · Clase II · Cerrado por la FDA · D-0605-2017 · Atenolol

    Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.

    ATENOLOL Tablets, USP, 50 mg, packaged in a) 100-count bottles (NDC 68382-023-01) and b) 1000-count bottles (NDC 68382-023-10), Rx only, Manufactured by: Cadila Healthcare Ltd., India; Distributed by: Zydus Pharmaceutica

2016

  1. 2 de noviembre de 2016 · Clase III · Cerrado por la FDA · D-0207-2017 · Bupropion

    Failed Dissolution Specifications; 6 month time point

    BuPROPion Hydrochloride Extended-Release Tablets (XL), 300 mg, Rx Only, a) 30 count bottles (NDC 68382-354-06) and b) 500 count bottles (NDC 68382-354-05), Manufactured by: Cadila Healthcare LTD. Ahmedabad, India Distrib

  2. 3 de agosto de 2016 · Clase III · Cerrado por la FDA · D-0149-2017 · Bupropion

    Failed Dissolution Specifications: Product did not meet dissolution specification at an intermediate time point.

    BuPROPion Hydrochloride Extended-Release Tablets, USP (XL) 300 mg, Rx Only, 500-count bottles, Manufactured by Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA inc. Pennington, NJ 08534,

  3. 19 de julio de 2016 · Clase II · Cerrado por la FDA · D-1460-2016 · Venlafaxine

    Failed Dissolution Specifications: out of specification dissolution results in retained samples

    Venlafaxine HCL ER Capsule USP, 150mg, packaged in a) 30-count bottles (NDC 68382-036-06), b) 90-count bottles (NDC 68382-036-16), and c) 1000-count bottles, (NDC 68382-036-10), Rx only, Manufactured by : Cadila Healthca

  4. 19 de julio de 2016 · Clase II · Cerrado por la FDA · D-1461-2016 · Venlafaxine

    Failed Dissolution Specifications: out of specification dissolution results in retained samples

    Venlafaxine HCL ER Capsule USP, 75mg, packaged in a) 30-count bottles (NDC 68382-035-06), b) 90-count bottles (NDC 68382-035-16), and c) 1000-count bottles, (NDC 68382-035-10), Rx only, Manufactured by : Cadila Healthcar

  5. 9 de mayo de 2016 · Clase II · Cerrado por la FDA · D-1491-2016 · Bromocriptine mesylate

    Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.

    Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06

Se muestran los 60 más recientes de 66.

¿Qué significan las clases de retiro?

Clase I: El tipo más grave: existe una probabilidad razonable de que usar el producto cause problemas de salud graves o la muerte.
Clase II: Usar el producto puede causar problemas de salud temporales o reversibles con tratamiento, o la probabilidad de problemas graves es remota.
Clase III: No es probable que usar el producto cause problemas de salud (por ejemplo, un problema de etiquetado o de envase).

Fuentes

  1. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  2. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  3. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026

Buscador de informes de retiros de la FDA → · Informar un error →